DiaMedica Net Working Capital from 2010 to 2026
| DMAC Stock | USD 7.90 0.50 5.95% |
Net Working Capital | First Reported 2020-03-31 | Previous Quarter 27 M | Current Value 51 M | Quarterly Volatility 11.9 M |
Check DiaMedica Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among DiaMedica Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 33.3 K, Interest Expense of 426.2 K or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 49.24, Dividend Yield of 0.0 or PTB Ratio of 5.09. DiaMedica financial statements analysis is a perfect complement when working with DiaMedica Therapeutics Valuation or Volatility modules.
DiaMedica | Net Working Capital | Build AI portfolio with DiaMedica Stock |
Analyzing DiaMedica Therapeutics's Net Working Capital over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Working Capital has evolved provides context for assessing DiaMedica Therapeutics's current valuation and future prospects.
Latest DiaMedica Therapeutics' Net Working Capital Growth Pattern
Below is the plot of the Net Working Capital of DiaMedica Therapeutics over the last few years. It is DiaMedica Therapeutics' Net Working Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in DiaMedica Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Working Capital | 10 Years Trend |
|
Net Working Capital |
| Timeline |
DiaMedica Net Working Capital Regression Statistics
| Arithmetic Mean | 17,326,235 | |
| Geometric Mean | 4,208,909 | |
| Coefficient Of Variation | 110.66 | |
| Mean Deviation | 17,075,335 | |
| Median | 7,518,000 | |
| Standard Deviation | 19,172,582 | |
| Sample Variance | 367.6T | |
| Range | 50.4M | |
| R-Value | 0.87 | |
| Mean Square Error | 97.2T | |
| R-Squared | 0.75 | |
| Slope | 3,292,703 | |
| Total Sum of Squares | 5881.4T |
DiaMedica Net Working Capital History
About DiaMedica Therapeutics Financial Statements
DiaMedica Therapeutics stakeholders use historical fundamental indicators, such as DiaMedica Therapeutics' Net Working Capital, to determine how well the company is positioned to perform in the future. Although DiaMedica Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in DiaMedica Therapeutics' assets and liabilities are reflected in the revenues and expenses on DiaMedica Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in DiaMedica Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Working Capital | 45.1 M | 29.7 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether DiaMedica Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of DiaMedica Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Diamedica Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Diamedica Therapeutics Stock:Check out the analysis of DiaMedica Therapeutics Correlation against competitors. For information on how to trade DiaMedica Stock refer to our How to Trade DiaMedica Stock guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Will Biotechnology sector continue expanding? Could DiaMedica diversify its offerings? Factors like these will boost the valuation of DiaMedica Therapeutics. Projected growth potential of DiaMedica fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every DiaMedica Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of DiaMedica Therapeutics is measured differently than its book value, which is the value of DiaMedica that is recorded on the company's balance sheet. Investors also form their own opinion of DiaMedica Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is DiaMedica Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because DiaMedica Therapeutics' market value can be influenced by many factors that don't directly affect DiaMedica Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between DiaMedica Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding DiaMedica Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, DiaMedica Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.